Through strategic research projects, joint development, licensing deals and joint ventures, ThromboGenics seeks to expand its activities with a focus on the development of innovative medicine.
ThromboGenics holds an equity stake in Oncurious NV. Incorporated in April 2015, this joint venture with the Flanders Institute for Biotechnology (VIB) is an oncology company focused on the development of innovative medicines for the treatment of pediatric brain tumors. Both ThromboGenics and VIB have contributed research and development know-how and patents to enable Oncurious to pursue the development of its first program: TB-403 for the treatment of pediatric brain tumor. BioInvent International AB acts as a co-development partner for this project.
Find out more at www.oncurious.com.